NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.284; Bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of ovarian cancer and No.285; Bevacizumab for the treatment of recurrent or advanced

ovarian cancer

**Matrix of consultees and commentators**

|  |  |
| --- | --- |
| **Consultees** | **Commentators (no right to submit or appeal)** |
| Company/sponsor* Roche Products (bevacizumab)

Patient/carer groups* Black Health Agency
* Cancer 52
* Cancer Black Care
* Cancer Equality
* Eve Appeal
* HAWC
* Helen Rollason Cancer Charity
* Independent Cancer Patients Voice
* Macmillan Cancer Support
* Maggie’s Centres
* Marie Curie
* Muslim Council of Britain
* Ovacome
* Ovarian Cancer Action
* Rarer Cancers Foundation
* South Asian Health Foundation
* Specialised Healthcare Alliance
* Target Ovarian Cancer
* Tenovus Cancer Care
* The Robin Cancer Trust
* Wellbeing of Women
* Women’s Health Concern

Professional groups* Association of Anaesthetists
* Association of Cancer Physicians
* Association of Surgeons of Great Britain and Ireland
* British Geriatrics Society
* British Gynaecological Cancer Society
* British Institute of Radiology
* British Psychosocial Oncology Society
* British Society of Urogynaecology
* Cancer Research UK
* National Forum of Gynaecological Oncology Nurses
* Royal College of Anaesthetists
* Royal College of General Practitioners
* Royal College of Nursing
* Royal College of Obstetricians & Gynaecologists
* Royal College of Pathologists
* Royal College of Physicians
* Royal College of Radiologists
* Royal College of Surgeons
* Royal Pharmaceutical Society
* Royal Society of Medicine
* Society and College of Radiographers
* UK Clinical Pharmacy Association
* UK Health Forum
* UK Oncology Nursing Society

Others* Department of Health
* NHS England
* NHS Rotherham CCG
* NHS Surrey Downs CCG
* Welsh Government
 | General commentators* Allied Health Professionals Federation
* Board of Community Health Councils in Wales
* British National Formulary
* Care Quality Commission
* Department of Health, Social Services and Public Safety for Northern Ireland
* Healthcare Improvement Scotland
* Medicines and Healthcare Products Regulatory Agency
* National Association of Primary Care
* National Pharmacy Association
* NHS Alliance
* NHS Commercial Medicines Unit
* NHS Confederation
* Scottish Medicines Consortium

Comparators* Accord Healthcare (carboplatin, cisplatin, gemcitabine, pegylated liposomal doxorubicin hydrochloride, topotecan)
* Allergan (gemcitabine, topotecan)
* AstraZeneca (olaparib)
* Celgene (paclitaxel)
* Eli Lilly (gemcitabine)
* Hospira UK (carboplatin, cisplatin, gemcitabine, topotecan)
* Janssen-Cilag (pegylated liposomal doxorubicin hydrochloride)
* Medac (gemcitabine, pegylated liposomal doxorubicin hydrochloride, topotecan)
* Novartis (topotecan)
* Pfizer (pegylated liposomal doxorubicin hydrochloride)
* Sandoz (cisplatin)
* Sun pharmaceuticals (carboplatin, gemcitabine)
* Teva (pegylated liposomal doxorubicin hydrochloride)

Relevant research groups* Cochrane Gynaecological Cancer Group
* Institute of Cancer Research
* MRC Clinical Trials Unit
* National Cancer Research Institute
* National Cancer Research Network
* National Institute for Health Research
* Ovarian & Prostate Cancer Research Trust

Associated Public Health Groups* Public Health England
* Public Health Wales
 |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.